Scandinavian Biopharma enters into a commercial collaboration with Novavax in Sweden
Scandinavian Biopharma and Novavax have signed a commercial collaboration agreement for the Covid vaccine Nuvaxovid. As of October 2022, the company is the representative for Nuvaxovid on the Swedish market and will assist Novavax with the sales and marketing of the vaccine. Nuvaxovid is an adjuvanted protein-based vaccine that protects against SARS Covid-19.